Skip to main content

The burden of Japanese encephalitis, the catch-up vaccination campaign, and health service providers’ perceptions in Myanmar: 2012–2017



Myanmar is endemic for Japanese encephalitis (JE) and has experienced several outbreaks in recent years. The vector-borne disease control (VBDC) program has collected hospital-based surveillance data since 1974. There is an urgent need to collate, analyze, and interpret the most recent information. The study aimed to describe (i) hospital-based JE cases and deaths between 2012 and 2017, (ii) a catch-up vaccination campaign in children in 2017, and (iii) health service provider perceptions about JE in one township in 2018.


This was a cross-sectional study of cases, deaths, and catch-up childhood vaccinations using secondary data from program records and a survey database of health service provider perceptions.


Between 2012 and 2017, there were 872 JE cases and 79 deaths with a case fatality rate of 91 per 1000; 2016 was the year with most cases and deaths. Most cases (n = 324) and deaths (n = 37) occurred in children aged 5–9 years. Large case numbers were reported in delta and lowland regions (n = 550) and during the wet season (n = 580). The highest case fatality rates were observed in the hills and coastal regions (120 and 112 per 1000, respectively). Nationwide coverage of the catch-up JE vaccination campaign among 13.7 million eligible children was 92%, with coverage lower in the hills and coastal regions (84%) compared with delta and lowland regions and plains (94%). More vaccinations (65%) occurred through school-based campaigns with the remainder (35%) vaccinated through community-based campaigns. Structured interviews in one township showed that service providers (n = 47) had good perceptions about various aspects of JE, although perceived benefits of specific vector control measures were poor: spraying/fumigation (38%), garbage removal (36%), larvicide use (36%), and drainage of standing/stagnant water (32%).


The catch-up vaccination campaign was a successful response to high JE case numbers and deaths in children. However, ongoing surveillance for JE needs to continue and be strengthened to ensure comprehensive reporting of all cases, more knowledge is needed on disability in JE survivors, and all attempts must be made to ensure high percentage coverage of vaccination through routine and catch-up campaigns.


Japanese encephalitis (JE) is an acute inflammatory disease caused by the Japanese encephalitis virus (JEV), 1 of 70 viruses in the Flavivirus genus of the family Flaviviridae. It is the main cause of viral encephalitis in Asia and a large area of the Western Pacific with an estimated 68,000 clinical cases of encephalitis every year [1]. It is mosquito-borne, with the main vector in tropical and subtropical regions being Culex tritaeniorhynchus, which bites mainly at night [1]. The virus is maintained and amplified by intermediate hosts, primarily pigs and wading birds. Transmission to humans not only occurs most frequently in agricultural areas such as farms and rice paddies, but also occurs in peri-urban or urban areas with appropriate ecological conditions. More than 3 billion people are at risk of transmission [1]. The occurrence of JE is seasonal in temperate climes with the main period of risk being May to October, but in tropical regions, the risk is all year round.

In endemic countries, like Myanmar, symptomatic JE is generally reported in children. Of individuals who are infected, less than 1% will progress to encephalitis [2]. Of the 68,000 estimated clinical cases of encephalitis each year, between 20–30% die and 30–50% of survivors have significant neurological or psychiatric sequelae [3]. Individuals who live in or have traveled to a JE-endemic area and develop encephalitis are considered a suspected JE case, and confirmatory diagnosis is through laboratory testing of serum or cerebrospinal fluid (CSF). There is no specific antiviral treatment for JE and treatment is supportive. Safe and effective vaccines are available to prevent disease, with new generation JE vaccines gradually replacing those derived from mouse brains [1, 2, 4, 5]. It seems clear that where vaccination coverage is poor, there is a higher risk of JE especially among children [6], but even in areas where JE vaccination programs have developed or are becoming established, the incidence of JE can remain quite substantial [7].

JE was first reported as an outbreak in Tarchileik Township, Shan State, Myanmar, in 1974, and over the next 5 years, Shan State reported outbreaks on an annual basis. More recently and from 2010, JE outbreaks have been reported from 13 states/regions of Myanmar, with just over 50% of cases occurring in rural populations [8,9,10,11]. In 2016, there were serious outbreaks of JE, and in mid-August 2017, the Department of Public Health, Myanmar, reported 404 cases of JE from 14 states/regions and Nay Pyi Taw Council Territory. Despite the growing importance of JE in Myanmar, the attention of service providers to provide an adequate coordinated response in a “one health approach to reduce zoonotic epidemic threats” has been limited. There have been gaps in public–private partnerships and poor coordination between health authorities, veterinarians, and the public in terms of education campaigns, vector control measures, vaccination of at-risk populations, and epidemic preparedness and response.

To address these gaps, in 2017, a nationwide JE vaccination catch-up campaign was started for schools and the community. Data were also collected from selected service providers about their knowledge, attitudes, and perceptions towards the disease and its prevention. The published and reported data on JE in Myanmar is local and fragmented [8, 9, 11], and there is a great need to have a comprehensive situational analysis of country-wide hospital-based cases over a 6-year period. This data, combined with information about the recent 2017 catch-up vaccination campaign and perspectives from service providers, will be valuable for the vector-borne disease control (VBDC) program and the Expanded Programme on Immunization (EPI) under the Department of Public Health, Ministry of Health and Sports, so that they can develop a new coordinated strategic plan to successfully reduce JE transmission in the country.

The aim of this study, therefore, was to describe the burden of hospital-based Japanese encephalitis, the vaccination campaign, and health service provider perceptions about the disease and its prevention in Myanmar. Specific objectives were to describe (i) the hospital-based cases with JE in Myanmar, associated characteristics, and deaths over a 6-year period from 2012 to 2017; (ii) the number of children vaccinated in the JE vaccination catch-up campaign in 2017; and (iii) health service provider perceptions about JE, its transmission, and prevention in one township, Bago Region in 2018.


Study design

This was a cross-sectional descriptive study using secondary data from program records and one survey database.


General setting

Myanmar is located in the South East Asia Region, neighboring the Republic of China on the north and northeast, Laos on the east, Thailand on the southeast, Bangladesh on the west, and India on the northwest. The country is separated administratively into Nay Pyi Taw Council Territory and 14 states and regions. It consists of 74 districts, 330 townships, 398 towns, 3065 wards, 13,619 village tracts, and 64,134 villages. The main terrestrial features of the country are the delta region and the central plain surrounded by mountains. Myanmar enjoys a tropical climate with three different seasons: rainy, cold, and hot. In 2014, Myanmar had a population of about 52 million people with an urban–rural population ratio of 30:70 [12]. It has an area of 676,577.2 km2 and a population density per square kilometer of 76.1 [12].

JE and its prevention and control in Myanmar

In Myanmar, JE was included as one of the five principal epidemic diseases in 1976. However, in 1989, JE lost this status although in 1995 it was made a notifiable disease. From 2000 onwards, JE was included in the meningitis/encephalitis disease entity in the National Health Management Information System (HMIS), and surveillance of the acute encephalitis syndrome (AES) was initiated in 2007. The prevention and control of JE outbreaks involve a mixture of activities that include case studies, active case finding, serological surveys, entomological studies, adult vector control measures, and health education in schools and the community [10]. The current National JE Control Strategy from the Department of Public Health for prevention and control of JE is in line with the strategy agreed at the sixth bi-regional meeting on JE for the WHO South-East Asia and Western Pacific regions held in May 2014 [13], the key components of which are (i) adult mosquito control, (ii) mosquito breeding control, and (iii) human vaccination. The two components missing in the Myanmar health sector from the WHO strategy are vaccination of pigs and improved living conditions.

JE case surveillance

Serological surveys have been conducted in Myanmar since 1968 when the existence of the disease in the country was first discovered [10]. The earliest clinical case was recorded in 1974 in Tarchileik Township in the Eastern Shan State. Annual outbreaks of JE with considerable morbidity and mortality occurred between 1974 and 1979 with case fatality rates ranging between 50 and 100%. Between 1974 and 2011, thirty-eight townships of eight states and seven regions reported a total of 259 clinical cases of JE with 106 deaths, giving an overall case fatality of 41%. In 2012, seven townships of one state (Rakhine) and two regions (Yangon and Tanintharyi) reported 13 cases of Japanese encephalitis with no deaths, and in all these areas, apart from Hpa-an, Kayin State, the disease was serologically confirmed. In Kyaing Tone and Taunggyi of Shan State, JE outbreaks occurred over four consecutive years from 2012 to 2015. JE case surveillance is currently conducted jointly by the Department of Public Health and the Department of Medical Services in line with national guidelines [14].

JE case management, vector control measures, and recording/reporting

Patients admitted to hospital with AES are suspected to have JE. In these situations, hospital staff work in collaboration with teams from the VBDC program to collect blood (3 ml of venous blood) and cerebrospinal fluid (0.5 ml of CSF) specimens, and these are sent to the National Health Laboratory in Yangon, which was under the Department of Public Health up to 2015, since when it has been under the Department of Medical Services. Diagnostic confirmation is done through serological testing and CSF examination for JE viral-specific antibodies using the JE IgM ELISA Test Kit “JE Detect™ IgM Antibody Capture ELISA (Mac-ELISA)” from InBios International, Inc., WA, USA [15]. Because JE virus can cross-react with dengue virus on antibody testing, the National Health Laboratory follows WHO Guidelines for confirming JE virus infection [16]. This works as follows. Any serum showing a positive JE IgM test result is retested using InBios Dengue Detect IgM Antibody Capture ELISA [17]: if this test is negative, the serum is reported as JE positive, and if the test is positive, the serum is reported as dengue positive. Serum with equivocal results from the dengue testing is retested with the reporting algorithm similar to the above except that a second equivocal test is reported as JE positive. All JE-positive and JE equivocal tests are sent to the WHO regional reference laboratory for confirmatory testing. Standard operational definitions for AES and JE are shown in Table 1 [18]. Confirmed JE cases are notified to the Department of Public Health that then authorizes JE source reduction measures. VBDC officers take responsibility for instituting adult mosquito control measures (space spraying/thermal fogging using malathion insecticide) in the urban ward or village where the index patient resides.

Table 1 Operational definitions for acute encephalitis syndrome and Japanese encephalitis

Records of JE cases are kept at the hospital, and a focal person from the VBDC team collects these on a weekly basis through fax, electronic mail, and phone calls. During JE outbreaks, the collection of reports is daily rather than weekly. These case records are collated by focal persons of the VBDC team who transfer the data upwards from township to district to state/region and finally to the Central VBDC Programme at the Department of Public Health. The Central VBDC Programme reports weekly to the Ministry of Health and Sports, and from there, reports are sent to WHO SEARO through the WHO Country Office of Myanmar.

JE vaccination campaign

In 2017, the EPI undertook a nationwide JE vaccination catch-up campaign supported by funds from the Global Alliance for Vaccines and Immunizations (GAVI). The purpose of this was to provide high immunity to JE before JE vaccines were incorporated onto the national routine immunization schedule in 2018. Technical support was provided by WHO, the United Nations Children’s Fund (UNICEF), and the Programme for Appropriate Technology in Health (PATH). Nearly 14 million children (aged 9 months to 15 years) were targeted using the WHO pre-qualified live attenuated (SA 14-14-2) JE vaccine, which is the same one to be used in the routine immunization schedule. The campaign was launched in two phases: a school-based phase targeting 5–15-year-old students between 15 and 23 November 2017 and a community-based phase targeting children aged 9 months to 5 years (out-of-school) between 11 and 20 December 2017 [19].

Service provider perceptions in Letpadan Township, Bago Region

Bago Region includes 28 townships and about 4.8 million inhabitants. There are three distinct seasons in the region that are hot (March to May), wet (May to October), and cool (November to February). Between 2012 and 2017, there were 121 reported cases of JE and eight associated deaths. Letpadan Township was one of the five townships in Bago Region with a high number of cases and deaths [20]. In January 2018, a team from the Department of Medical Research conducted structured interviews in Letpadan Township following the JE vaccination catch-up campaigns. These interviews were carried out among service providers which included VBDC staff, health assistants, lady health visitors, public health supervisors, and midwives. The selection of participants for interviews was purposive so as to have comprehensive representation at the township level. Ethics approval for this particular survey was obtained from the Ethics Review Committee of the Department of Medical Research (Ethics/DMR/2018/008).

Study population

The study included (i) all patients diagnosed with JE in hospitals in Myanmar between 2012 and 2017, (ii) children vaccinated during the catch-up campaign in 2017 in both the school-based phase and community-based phase, and (iii) health service providers who were interviewed in the public sector in Letpadan Township, Bago Region.

Variables, data sources, and data collection

Data variables for the study included the following: for hospital-recorded cases of JE and deaths—year, month, age group, gender, urban/rural residence, season, and ecological area of the country for each case. The definition of ecological areas was adapted from Oo et al. [21] and is shown in Table 1. The source of data was the VBDC electronic EXCEL database for national aggregate data; for vaccinated children—ecological region, children eligible for vaccination, children vaccinated, children vaccinated during the school-based campaigns, and children vaccinated during the community-based campaigns. The source of data was the electronic EXCEL database for aggregate data obtained from the 2017 EPI records and donor reports; for health service provider perceptions—these were structured wide-ranging questions related to perceptions, attitudes, and opinions about JE and its prevention. The data source was secondary data from the survey database of the DMR that focused on Letpadan Township, Bago Region.

Analysis and statistics

Data were extracted and cleaned in an EXCEL file and exported to EpiData software (version for analysis, EpiData Association, Odense, Denmark). A descriptive analysis was performed on JE cases, JE deaths, and results of the vaccination campaign using frequencies and proportions. Hospital-based JE case fatality rates were calculated by the number of deaths per 1000 JE cases per year. Cases and deaths were analyzed in relation to certain characteristics such as age group, gender, urban/rural residence, season, and ecological region. Maps of JE cases and deaths at state and regional levels were generated through a geographical information system using QGIS [22]. Perceptions, attitudes, and opinions of health service providers were analyzed by frequencies and percentages.


Hospital-recorded cases of JE and JE deaths

The annual number of hospital-reported cases of JE and associated deaths are shown in Figs. 1 and 2. During the 6-year period, there was a total of 872 JE cases and 79 JE deaths, with an overall case fatality rate of 91 per 1000 cases. In 2016 and 2017, there was an increase in the number of cases at 404 and 244, respectively, while during the other 4 years, the number of cases ranged from 13 to 114. Case notification rates per 100,000 were similar to the pattern seen with the absolute number of cases. The distribution of JE deaths each year mirrored the distribution of cases. The case fatality rate was highest in 2014 at 114 per 1000 JE cases, while in the other years, this ranged between 0 and 100 per 1000 cases.

Fig. 1
figure 1

Annual hospital-reported JE cases and case notification rates per 100,000 population in Myanmar: 2012 to 2017

Fig. 2
figure 2

Annual hospital-reported JE deaths and case fatality rates in Myanmar: 2012 to 2017

Demographic characteristics, seasonal changes, and the ecological distribution of all hospital-recorded JE cases and deaths between 2012 and 2017 are shown in Table 2. Approximately, 85% of all cases were in children, with those aged 5–9 years being the predominant age group affected. The highest case fatality rates were also observed in the age group 5–9 years. Males were more likely to have JE compared to females, but case fatality was higher in females. Those residing in rural settings were at higher risk of JE and death compared with urban settings. The majority of cases and deaths, and the highest case fatality rates, occurred in the wet season from May to September. Most cases (63%) and deaths (53%) occurred in persons living in the delta and lowland areas although case fatality was highest in those residing in the hills.

Table 2 Operational definitions ecological regions in Myanmar

Figure 3 is a map that shows JE cases and deaths in relation to the four ecological regions of the country. The five main hot spots for JE cases were Yangon, Ayeyawady, and Bago regions followed by Rakhine and Shan states. The main hot spots for JE deaths were Rakhine and Shan states followed by Yangon, Ayeyawady, and Bago regions.

Fig. 3
figure 3

Distribution of all hospital-reported JE cases and deaths in Myanmar between 2012 and 2017

Childhood vaccination campaign for 2017

Numbers and proportions of children vaccinated against JE during school-based and community-based catch-up campaigns in 2017 for the whole country and by ecological region are shown in Table 3. Nationwide coverage of JE vaccination among eligible children was 92%. Vaccination coverage was lower in the hills and coastal regions (84%) compared to delta and lowland regions and the plains (94%). Nearly two thirds of the children were vaccinated through school-based campaigns with the remainder vaccinated through community-based campaigns. These ratios of school-based to community-based campaigns were similar in the delta and lowlands, plains, and coastal regions, while in the hilly regions, school-based campaigns were fewer and constituted 58% of vaccination coverage.

Table 3 Demographic characteristics, seasonal changes, and the ecological distribution of hospital-recorded JE cases, JE deaths, and case fatality rates in Myanmar between 2012 and 2017

Perceptions, attitudes, and opinions of health service providers

Perceptions, attitudes, and opinions of 47 health service providers about JE infection in Letpadan Township, Bago Region, in January 2018, are shown in Table 4. Although 94% of health service providers accepted JE as a serious illness, their perceived risk about contracting JE and their increased risk of being a resident in the particular locality were just over 50% (Table 5). Over 90% of the health service providers showed a positive attitude towards the prevention of JE through compliance with VBDC guidelines. However, less than 40% believed that specific measures to prevent JE would be useful such as spraying to reduce the adult mosquito population, removing garbage dumps, using larvicides, and improving drainage. Over 90% of health service providers believed that epidemic surveillance of JE in humans and pigs and removal of the JE vectors (mosquitoes) would reduce JE transmission. Three quarters believed that JE vaccination should be given to children aged 9 months to 15 years. While less than 40% stated the need for stakeholders to be updated on JE, there was strong support for villagers to be educated about the disease through either community or school-based education sessions.

Table 4 Numbers and proportions of children vaccinated against JE during school-based and community-based catch-up campaigns in 2017 in Myanmar for the whole country and by ecological region
Table 5 Health service providers’ perceptions, attitudes, and opinions about JE infection and its prevention in Letpadan Township, Bago Region, Myanmar, in January 2018


This is the first study from Myanmar assessing the national burden and characteristics of hospital-reported JE cases and deaths over a 6-year period, documenting the results of the 2017 catch-up vaccination campaign in children and describing health service providers’ perceptions of JE and its prevention. There were a number of important findings.

There were nearly 900 reported cases of JE with a case fatality rate of 91 per 1000. The majority of cases and deaths occurred in children, particularly those aged 5–9 years. The year 2016 was the worst for absolute numbers of cases and deaths, which led to the catch-up vaccination campaign in 2017. This was an ecological study, and we therefore did not capture any information about morbidity after recovery from the infection. Previous reviews point to significant neurological sequelae being present in up to 50% of survivors [3, 23], so while this disease is less common in the country than dengue [21], it may nevertheless be very demanding on health service care and resources. While care is currently supportive, there is an ongoing work exploring the prospects for direct-acting antiviral treatment, especially with the use of nucleoside and nucleotide reverse transcriptase inhibitors [24, 25]. Two studies in India have evaluated the use of minocycline, and while there was some evidence of reduced symptom duration and hospital stay, there were no survival benefits [26, 27]. Finally, there has been some preliminary work on the use of intravenous immunoglobulin in Nepal [28], again without proof yet of survival benefit.

The finding that JE cases were more frequent in the wet season and in delta and lowland regions (with paddy fields and areas prone to flooding) aligns with current knowledge about transmission of JE in Asian countries [29, 30]. There are seasonal correlations in rural areas between mosquito abundance, JE virus seroconversion in pigs, and concurrent human JE outbreaks [29]. In the wet season, the widespread and timely implementation of mosquito larval control measures and space spraying of townships and wards with insecticides may help to contain mosquito proliferation and reduce human outbreaks. However, a recent report of increasing resistance of two important JE vectors (Culex tritaeniorhymchus and Culex vishnui) to DDT, malathion, and deltamethrin in India is of concern to the region [31]. Case fatality was higher in the hills, similar to what was found 2 years ago with dengue [21]. This may be because health facilities are not as well-resourced in these areas, health care workers are less experienced in providing supportive care for encephalitis, and there is poor immunity of the population to the JE virus.

It was encouraging to see the high uptake of JE vaccination in the 2017 catch-up campaign, especially in the delta and lowland areas where the burden of JE is highest. The SA 14-14-2 live attenuated JE vaccine, whether used on routine or campaign basis, has shown excellent and durable efficacy in China, Nepal, and South Korea [32], although results have been less impressive in India maybe as a result of cross-contamination from non-vaccinated to vaccinated districts [33]. Good surveillance will be needed in Myanmar to determine whether morbidity and mortality from JE are reduced through this strategy of a one-off catch-up vaccination campaign followed by routine immunization or whether further catch-up campaigns may be necessary, as is the case in Nepal [34].

Finally, the structured interviews in the township showed that service providers had a reasonable degree of knowledge about the serious nature of JE, the need for epidemic surveillance in humans and pigs, the importance of JE vaccination of children and about the value of regularly updated education of rural populations about JE. Knowledge related to specific vector control measures was poor, and this needs to be improved. There have been no recent published studies on knowledge, attitude, or practice of service providers in relation to JE in Myanmar with which to compare these findings.

The strengths of the study were the hospital-recorded cases and deaths of JE from all health facilities in all states and regions of the country over a 6-year period, making the findings representative of what is happening in the country. The conduct and reporting of this observational study were also in line with internationally recommended Strengthening the Reporting of Observational Studies in Epidemiology (STROBE guidelines) [35].

However, there were a number of limitations. First, we do not know how well or comprehensively all children in the country with acute encephalitis syndrome (AES) were investigated for JEV. In Mandalay hospital, four of 123 children presenting with acute encephalitis had JEV diagnosed in their CSF by neutralization tests and/or virus isolation [11], but if the tests are not performed on all children presenting with AES, the diagnosis will be missed. While it is likely that children with AES are admitted to the hospital given the serious nature of this condition, cases may develop quickly and die in the community. Our hospital-based recording system may therefore have underestimated the true burden of JE in the country. Second, we also had no information about the clinical profile of JE patients, the time that they spent in hospitals and among the survivors the degree of disability and dysfunction, so the burden of disease on the health care services is not known. Third, while the vaccination uptake among eligible children was high, we do not know the reasons why some children, particularly in the hills and coastal areas, did not receive the vaccination. This is important because widespread and complete vaccination coverage is needed to control this disease [23].

Despite these limitations, there are a number of programmatic implications. First, ongoing surveillance of hospital-based cases and deaths must continue and be strengthened with oversight to ensure that all AES cases are fully investigated for JE. Second, Myanmar should undertake a prospective evaluation of the neurological sequelae and disability resulting from JE and use this locally generated evidence to better inform the health care services and the general public about the seriousness of the disease and the need for its prevention. In this regard, the country could consider whether to use a new outcome score based on a 15-item questionnaire which has been successfully developed and tested by the WHO to assess the severity of disability resulting from JE in children and whether the child is likely to be dependent [36].

Third, every attempt must be made to ensure that the SA 14-14-2 live attenuated JE vaccine is fully incorporated into childhood routine immunization schedules, with ongoing surveillance needed to determine whether additional catch-up vaccination campaigns are needed, as is the case in Nepal [34]. Ultimately, JE is a vaccine-preventable disease, and high percentage coverage with routine as well as catch-up campaigns is the intervention most likely to control and even eliminate the disease. Unfortunately, there has been a gradual shift in JEV genotypes in Asia over the years, especially from genotype III to genotype I [37]. Almost all currently available vaccines are developed against the genotype III strains of JE, so this genotypic shift raises concerns about vaccine efficacy. Studies have shown that these vaccines are effective against genotype I [38], but less so against genotype V [39]. In light of these findings, Myanmar needs to decide how much effort and investment is also needed to vaccinate domestic pigs and undertake vector control. This would be in line with a coordinated “one health approach.” JEV in adult pigs does not result in symptomatic disease, but pigs can suffer from significant reproductive problems that include abortion, still-birth, and birth defects [40]. Protective vaccines are available for both pigs and horses [40].


This study has described the burden of hospital-recorded JE in Myanmar between 2012 and 2017. The disease was concentrated in children and seen particularly in the delta and lowland regions and during the wet season. Overall case fatality was 91 per 1000, with high rates observed in children aged 5–9 years and people residing in hills and coastal regions. The catch-up JE vaccination campaign through school-based and community-based phases was successful with an overall 92% coverage although this was lower in the hills and coastal regions. Structured interviews in one township showed that service providers had a reasonable degree of knowledge about various aspects of JE, although this was poor with respect to specific vector control measures. For the future, ongoing surveillance for JE needs to continue and be strengthened, more knowledge is needed on disability in JE survivors, and all attempts must be made to ensure high percentage coverage of vaccination through routine and catch-up campaigns.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.



Case fatality rate


Cerebrospinal fluid


Expanded Program on Immunization


Japanese encephalitis


Vector-borne disease control


World Health Organization


  1. World Health Organization. Japanese encephalitis fact sheet. 2019. WHO, Geneva, Switzerland. Available: (Accessed 27 May 2019).

  2. Hills SL, Rabe IB, Fischer M. Japanese encephalitis. Infectious Diseases Related to Travel. May 2017; Chapter 3. Available: (Accessed 27 May 2019).

  3. Erlanger T, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg Infect Dis. 2009;15:1–7.

    Article  Google Scholar 

  4. World Health Organization. Japanese encephalitis vaccines: WHO position paper–February 2015. WHO. Wkly Epidemiol Rec. 2015;90:69–88.

    Google Scholar 

  5. Japanese encephalitis morbidity, mortality, and disability. Reduction and Control by 2015. Available: (accessed 27 May 2019).

  6. Kakkar M, Chaturvedi S, Saxena VK, Dhole TN, Kumar A, Rogawski ET, et al. Identifying sources, pathways and risk drivers in ecosystems of Japanese encephalitis in an epidemic-prone north Indian district. PLoS One. 2017;12:e0175745.

    Article  Google Scholar 

  7. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89:766–74.

    Article  Google Scholar 

  8. Thein S, Aung H, Sebastian AA. Study of vector, amplifier, and human infection with Japanese encephalitis virus in a Rangoon community. Am J Epidemiol. 1988;128:1376–82.

    Article  CAS  Google Scholar 

  9. Mon-Oo P, Hlaing T, Lwin S, Pittyawonganon C, Srichasinthop J, Khine SK. A large outbreak of Japanese encephalitis in Rakhine State, Myanmar: implications for vaccine policy. Outbreak Surveill Investig Rep (OSIR). 2016;9:8–15.

    Google Scholar 

  10. Vector Borne Disease Control Programme, Myanmar 2015-Annual Report. Ministry of Health and Sports, Myanmar. Available: (Accessed 27 May 2019).

  11. Kyaw AK, Ngwe Tun MM, Nabeshima T, Buerano CC, Ando T, Inoue S, et al. Japanese encephalitis- and dengue-associated acute encephalitis syndrome cases in Myanmar. Am T Trop Med Hyg. 2019;100:643–6.

    Article  CAS  Google Scholar 

  12. Department of Population, Ministry of Immigration and Population, The Republic of the Union of Myanmar. The 2014 Myanmar Population and Housing Census. Union Rep. 2015:1–263.

  13. World Health Organization. Prevention and control of Japanese encephalitis (JE). Report of the sixth Bi-regional meeting Bangkok, Thailand, 27-29 May 2014. WHO SEARO. Available: (Accessed 27 May 2018).

  14. Myanmar National Health Plan 2017-2021. Ministry of Health and Sports, The Republic of the Union of Myanmar, December 2016. Available: (Accessed 10th July 2018).

  15. JE IgM Elisa Test Kit “JE Detect™ IgM Antibody Capture ELISA (Mac-ELISA). InBios. International, Inc., Washington, USA. Available: (Accessed 13th September 2019).

  16. World Health Organization. Manual for the laboratory diagnosis of Japanese encephalitis virus infection. For evaluation purposes. 2007. WHO, Geneva, Switzerland. Available: (accessed 5 December 2019).

  17. DENV Detect IgM CAPTURE ELISA. In Bios. International, Inc., Washington, USA. Available: (accessed 5 December 2019).

  18. Lee DW, Choe YJ, Kim JH, Song KM, Cho H, Bae GR, et al. Epidemiology of Japanese encephalitis in South Korea, 2007 – 2010. Int J Infect Dis. 2012;16:e448–52.

    Article  Google Scholar 

  19. World Health Organization. Japanese encephalitis vaccination campaign in November and December 2017, Myanmar. Available: (accessed 27 May 2019).

  20. Annual Reports (2012-2017), Bago VBDC, Department of Public Health, Ministry of Health and Sports, Myanmar (hard copies available).

  21. Oo PM, Wai KT, Harries AD, Shewade HD, Oo T, Thi A, et al. The burden of dengue, source reduction measures, and serotype patterns in Myanmar, 2011-2015. BMC Trop Med Health. 2017;45:35.

    Article  Google Scholar 

  22. QGIS. A free and open source geographic information system (3.6 Noosa). Available: (accessed 27 May 2019).

  23. Basu A, Dutta K. Recent advances in Japanese encephalitis. F1000 Research 2017; 6(F1000 Faculty Rev): 259.

    Article  Google Scholar 

  24. Turtle L, Solomon T. Japanese encephalitis—the prospects for new treatments. Nat Rev Neurol. 2018;14:298–313.

    Article  Google Scholar 

  25. Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, et al. Nucleoside analogs with selective antiviral activity against dengue fever and Japanese encephalitis. Antimicrob Agents Chemother. 2019.

  26. Kumar R, Basu A, Sinha S, Das M, Tripathi P, Jain A, et al. Role of oral minocycline in acute encephalitis syndrome in India – a randomized controlled trial. BMC Infect Dis. 2016;16:67.

    Article  Google Scholar 

  27. Singh AK, Mehta A, Kushwaha KP, Pandey AK, Mittal M, Sharma B, et al. Minocycline trial in Japanese encephalitis: a double blind, randomized placebo trial. Int J Pediatr Res. 2016;3:371–7.

    Google Scholar 

  28. Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Ledger E, Bista KP, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS ONE. 2015;10:e0122608.

    Article  Google Scholar 

  29. Baruah A, Hazarika RA, Barman NN, Islam S, Gulati BR. Mosquito abundance and pig seropositivity as a correlate of Japanese encephalitis in human population in Assam, India. J Vector Borne Dis. 2018;55:291–6.

    Article  Google Scholar 

  30. Kulkarni R, Sapkal GN, Kaushal H, Mourya DT. Japanese encephalitis: a brief review on Indian perspectives. Open Virol. 2018;12:121–30.

    Article  Google Scholar 

  31. Sahu SS, Sonia T, Dash S, Gunasekaran K, Jambulingam P. Insecticide resistance status of three vectors of Japanese encephalitis in east-central India. Med Vet Entomol. 2019;33:213–9.

    Article  CAS  Google Scholar 

  32. Hegde NR, Gore MM. Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. 2017;13:1320–37.

    Article  Google Scholar 

  33. Muniaraj M, Rajamannar V. Impact of SA 14-14-2 vaccination on the occurrence of Japanese encephalitis in India. Hum Vaccin Immunother. 2019;15:834–40.

    Article  Google Scholar 

  34. Turtle L, Brindle HE, Schluter WW, Faragher B, Rayamajhi A, Bohara R, et al. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: a case for further catch up campaign? PloS Negl Trop Dis. 2019;13:e0007269.

    Article  Google Scholar 

  35. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative STROBE. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85:867–72.

    Article  Google Scholar 

  36. Lewthwaite P, Begum A, Ooi M, Faragher B, Lai BF, Sadaradura I, et al. Disability after encephalitis: development and validation of a new outcome score. Bull World Health Organ. 2010;88:584–92.

    Article  Google Scholar 

  37. Pan XL, Liu H, Wang HY, Fu SH, Liu HZ, Zhang HL, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol. 2011;85:9847–53.

    Article  CAS  Google Scholar 

  38. Liu X, Yu Y, Li M, Liang G, Wang H, Jia L, et al. Study on the protective efficacy of SA 14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine. 2011;29:2127–30.

    Article  CAS  Google Scholar 

  39. Cao L, Fu S, Gao X, Li M, Cui S, Li X, et al. Low protective efficacy of the current Japanese encephalitis vaccine against the emerging genotype 5 Japanese encephalitis virus. PLoS Negl Trop Dis. 2016;10:e0004686.

    Article  Google Scholar 

  40. Mansfield KL, Hernandez-Triana LM, Banyard AC, Fooks AR, Johnson N. Japanese encephalitis virus infection, diagnosis and control in domestic animals. Vet Microbiol. 2017;201:85–92.

    Article  Google Scholar 

Download references


This research was conducted through the Structured Operational Research and Training Initiative (SORT IT), a global partnership led by the Special Programme for Research and Training in Tropical Diseases at the World Health Organization (WHO/TDR). The model is based on a course developed jointly by the International Union Against Tuberculosis and Lung Disease (The Union) and Medecins Sans Frontieres (MSF/Doctors Without Borders). The specific SORT IT program which resulted in this publication was jointly organized and implemented by The Centre for Operational Research, The Union, Paris, France; Department of Medical Research, Ministry of Health and Sports, Yangon; Department of Public Health, Ministry of Health and Sports, Nay Pyi Taw; The Union Country Office, Mandalay, Myanmar; The Union South East Asia Office, New Delhi, India; and London School of Hygiene and Tropical Medicine, London, UK.


The training program, within which this paper was developed, was funded by the Department for International Development (DFID), London, UK. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The open-access publications costs were funded by the Department for International Development (DFID), UK, and La Fondation Veuve Emile Metz-Tesch (Luxembourg).

Author information

Authors and Affiliations



AYNW designed the study, collected and analyzed the data, and wrote the first draft. KTW, ADH, NTTK, TO, HHL, WPT, and ZL participated in the design of the study, data analysis, and manuscript writing. All authors participated in data interpretation and preparation of the manuscript, and all authors read and approved the final manuscript.

Corresponding author

Correspondence to Aung Ye Naung Win.

Ethics declarations

Ethics approval and consent to participate

Permission to use the secondary data for this study has already been obtained from the VBDC and EPI. Ethics approval in Myanmar was obtained from the Ethics Review Committee, Department of Medical Research (DMR), Ministry of Health and Sports, Myanmar (Ethics/DMR/2018/148). Ethics approval was also obtained from the Union Ethics Advisory Group (International Union against Tuberculosis and Lung Disease, Paris, France) (EAG number 39/18).

Consent for publication

Consent to publish was obtained from the Ministry of Health and Sports, Myanmar.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Win, A.Y.N., Wai, K.T., Harries, A.D. et al. The burden of Japanese encephalitis, the catch-up vaccination campaign, and health service providers’ perceptions in Myanmar: 2012–2017. Trop Med Health 48, 13 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Myanmar
  • Japanese encephalitis
  • Children
  • Death
  • Catch-up vaccination campaign
  • Health service provider perceptions